| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-04-13 | Eisai (Japan) Genomics (UK) | statistical analyses of large-scale multi-phenotype genetic association data | collaboration |
Technology - Services | Collaboration agreement | |
| 2015-04-13 | Bone Therapeutics (Belgium) | establishment of a new subsidiary in the US |
Bone diseases - Regenerative medicine | Establishment of a new subsidiary in the US | ||
| 2015-04-13 | Halozyme Therapeutics (USA - CA) | nomination |
Nomination | |||
| 2015-04-13 | MorphoSys (Germany) Janssen Biotech, a J&J company (USA - NJ) | guselkumab (CNTO1959) | psoriatic arthritis | R&D - research | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Milestone |
| 2015-04-11 | AstraZeneca (UK) Genomics England (UK) | GENE Consortium (Genomics Network for Enterprises Consortium) | collaboration |
Cancer - Oncology - Rare diseases | Collaboration agreement | |
| 2015-04-10 | Novo Nordisk (Denmark) | manufacturing facility in Russia | diabetes | opening of new premises | Metabolic diseases | Opening of new premises |
| 2015-04-10 | IBA (Belgium) Baptist Health South Florida (USA - FL) | proton therapy system | services contract |
Cancer - Oncology | Services contract | |
| 2015-04-09 | MyCartis | Diagnostic - Cancer - Oncology | Nomination | |||
| 2015-04-09 | Cortendo (Sweden) National Organization for Rare Disorders (NORD)® | collaboration |
Rare diseases | Collaboration agreement | ||
| 2015-04-09 | AOP Orphan (Austria) Rigi Healthcare (Switzerland) | Rigi Orphan Inc | establishment of a new subsidiary in the US |
Rare diseases | Establishment of a new subsidiary in the US | |
| 2015-04-09 | IBA (Belgium) Toshiba (Japan) | Proteus®ONE, carbon therapy solutions | collaboration |
Diagnostic - Cancer - Oncology | Collaboration agreement | |
| 2015-04-09 | Atyr Pharma (USA - CA) | nomination |
Cancer - Oncology - Genetic diseases - Rare diseases | Nomination | ||
| 2015-04-09 | Genticel (France) | nomination |
Nomination | |||
| 2015-04-09 | Aegerion Pharmaceuticals (USA - MA) | nomination |
Rare diseases - Genetic diseases - Metabolic diseases | Nomination | ||
| 2015-04-09 | Osiris Therapeutics (USA - MD) | nomination |
Regenerative Medicine | Nomination | ||
| 2015-04-09 | Serodus (Norway) | nomination |
Metabolic diseases - Renal diseases - Kidney diseases | Nomination | ||
| 2015-04-08 | Cellectis (France) | establishment of a new subsidiary in the US |
Cancer - Oncology | Establishment of a new subsidiary in the US | ||
| 2015-04-08 | PTC Therapeutics (USA - NJ) | nomination |
Neuromuscular diseases - Rare diseases | Nomination | ||
| 2015-04-08 | Ipsen (France) Hannover Medical School (Germany) | recombinant botulinum neurotoxin proteins | cancers, endocrinological diseases, neurological diseases | R&D |
Cancer - Oncology - Endocrinological diseases - Neurological diseases | R&D agreement |
| 2015-04-08 | RegenXBio (USA - MD) University of Pennsylvania (PA) University of Minnesota (MN) | AAV vectors | Hurler syndrome or mucopolysaccharidosis type I (MPS I), Hunter syndrome or mucopolysaccharidosis type II (MPS II) | R&D licensing |
Rare diseases - Genetic diseases | R&D agreement |
